Home › Calculator › CTMX Dividend Calculator 2026
CTMX Dividend DRIP Calculator 2026
53.91% YieldHealthcareCytomX Therapeutics, Inc. · NASDAQ
Price: $3.71 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When CTMX pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your CTMX snowball 📈
$10,000 in CTMX → $3163741861.45M in 10 years · $263,168,419,361,518.28/month
About CytomX Therapeutics, Inc. (CTMX) — Dividend Analysis 2026
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
Compare CTMX with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full CTMX DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CTMX position with:
🌍 CTMX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold CTMX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 53.91% | 51.11% | $5,391 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 45.82% | 43.02% | $4,582 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 43.13% | 40.33% | $4,313 / yr |
| 🇬🇧 UK ISA | 0% | 53.91% | 51.11% | $5,391 / yr |
| 🇬🇧 UK Taxable | 8.75% | 49.19% | 46.39% | $4,919 / yr |
| 🇨🇦 TFSA | 0% | 53.91% | 51.11% | $5,391 / yr |
| 🇨🇦 CA Taxable | 25% | 40.43% | 37.63% | $4,043 / yr |
| 🇦🇺 Super (pension) | 15% | 45.82% | 43.02% | $4,582 / yr |
| 🇦🇺 AU Taxable | 30% | 37.74% | 34.94% | $3,774 / yr |
| 🇩🇪 DE Taxable | 26.375% | 39.69% | 36.89% | $3,969 / yr |
| 🇫🇷 FR Taxable | 30% | 37.74% | 34.94% | $3,774 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 CTMX Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 CTMX Dividend Payment Schedule
CTMX pays quarterly — 4 times per year. Next ex-div: TBD.
📊 CTMX vs Healthcare Benchmarks
How CTMX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CTMX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ CTMX Insider Activity
No recent SEC filings reported in the last 90 days.Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CTMX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
CTMX (CytomX Therapeutics, Inc.) — 53.91% Dividend Yield Analysis
CytomX Therapeutics, Inc. (CTMX) is a healthcare stock currently trading at $3.71 with a dividend yield of 53.91%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (53.91%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.